PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives. | PCI is your world leading CDMO, truly spanning the cycle, connecting development and commercialization, de-risking the supply chain providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. Leading technology and continued investment enable us to address global outsourcing development needs throughout the product lifecycle. PCI offers a global network of innovative centers of excellence for the development, manufacturing, packaging, storage, and distribution of life changing therapies. Our aim is simple, to accelerate your product from development to commercialization as efficiently and cost-effectively as possible. | PCI Pharma is a global CDMO known for delivering seamless integrated end-to-end drug development, manufacturing, and packaging solutions across the product lifecycle with a strong focus on quality, flexibility, and innovation. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. Leading technology and continued investment enable us to address global outsourcing needs throughout the product lifecycle. We operate a global network of innovative centers of excellence for the development, manufacturing, drug-device combination assembly, packaging, storage, and distribution of life-changing therapies. Our world- leading sterile fill-finish and lyophilization capabilities combined with specialist contained manufacturing and packaging facilities dedicated to processing highly potent drug products are complemented by a global network of packaging facilities delivering a truly differentiated service. Our aim is simple, to accelerate your product from development to commercialization as efficiently and cost-effectively as possible.
PackGene Biotech
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution. | PackGene Biotech excels as a leader in Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services, focusing on adeno-associated virus (AAV), mRNA, plasmid DNA, and lentiviral vector (LVV) solutions. Catering to early-stage drug discovery, preclinical development, and cell and gene therapy trials, we offer cost-effective, reliable, and scalable production. Our π-Alpha 293 AAV High-yield Platform marks a significant leap in AAV production, increasing yields by up to tenfold and supporting large-scale AAV batches up to 1E+17vg, meeting most commercial and clinical project needs. We also provide scalable, custom plasmid DNA solutions for various project sizes, encompassing end-to-end design, production, and manufacturing. Our GMP plasmid Manufacturing Platform can accommodate production scales from 5L to 200L. Our services extend to comprehensive process development, analytical development, and cell banking support for AAV, LVV, and plasmid projects. Additionally, we specialize in mRNA and LNP solutions, supporting the full spectrum of drug and vaccine development from research to GMP production. Committed to fostering innovation in biotechnology and healthcare, PackGene offers advanced solutions tailored to the evolving demands of the industry.
OranssiBio Ltd.
Oranssibio Ltd. | OranssiBio is a premier Contract Development and Manufacturing Organization (CDMO) strategically headquartered in Shanghai’s Free Trade Zone, specializing in advanced cell and gene therapies. We partner with biotech innovators and research institutions worldwide, delivering comprehensive, end-to-end solutions from early-stage development to clinical supply manufacturing and regulatory-compliant release. Our state-of-the-art, plug-and-play technology platforms support a diverse range of modalities, including: • Plasmid DNA • Lentivirus & Adeno-Associated Virus (AAV) • mRNA Therapeutics • Cell Therapies: CAR-T, TILs, NKs, iPSCs, and MSCs With a focus on quality, speed, and cost efficiency, OranssiBio accelerates the translation of groundbreaking therapies from bench to bedside, empowering our partners to bring life-changing treatments to patients faster and more effectively.
OneSource Specialty Pharma
OneSource is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,400 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.
Oncomed Manufacturing a.s.
We are part of CDMO medac group – your reliable partner specialized in aseptic processing of injectables in clinical and commercial scale. We work is strategic partnership with our clients to provide customized solutions for aseptic manufacturing. | CDMO committed to delivering reliable, flexible support across the entire pharmaceutical value chain. Our capabilities include: • Manufacturing high- and low-potency injectables (vials and syringes) for international markets • Production of small- and large-molecule therapeutics, including complex biologics such as antibody-drug conjugates (ADCs) and oligonucleotides • Scalable batch production, tailored from clinical development through to full commercial supply | x
Northway Biotech
Northway Biotech is a global end-to-end biologics CDMO supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company’s wide-ranging expertise and vertically integrated service offerings translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities, while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius (Lithuania) and Waltham, MA (USA). | Northway Biotech is a global end-to-end CDMO specializing in protein-based biologics and gene therapies. With over 20 years of experience and 180+ successful client programs, we provide integrated solutions – from cell line development to manufacturing cGMP Drug Substance and Drug Product. Our cGMP facilities in Vilnius, Lithuania, and Waltham, MA, support rapid, scalable manufacturing from early development through clinical and commercial phases. Known for scientific excellence, regulatory compliance, and a collaborative approach, Northway Biotech helps clients accelerate biopharmaceutical process development and manufacturing with speed, precision, and flexibility. | Northway Biotech is a leading biologics CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client’s unique needs. For further information, please visit www.northwaybiotech.com.
NIPPON SHOKUBAI
Nippon Shokubai provides contract manufacturing (CDMO) services for oligonucleotide and peptide active pharmaceutical ingredients (APIs), often referred to as middle molecules. With our advanced, GMP-compliant facilities, we support every stage—from discovery through clinical trials to post-marketing. We also offer comprehensive solutions for manufacturing process development and analytical method development. We are also actively advancing drug delivery systems (DDS) that are critical for middle molecules. This includes developing substances for targeted delivery to disease sites and new biocompatible polymers for DDS, helping to optimize therapeutic outcomes. Capabilities ・Contract manufacturing (CDMO) of oligonucleotide APIs ・Contract manufacturing (CDMO) of peptide APIs ・Contract manufacturing (CDMO) of middle molecule APIs ・Process development ・Analytical development ・Technical transfer for manufacturing ・New biocompatible polymers (DDS and others) ・siRNA-delivery peptides ・Heteroduplex oligonucleotides | Using our own technology, we at NIPPON SHOKUBAI manufacture ethylene oxide, acrylic acids, catalysts, superabsorbent polymers and so on. We will continue to launch new products in ICT, Life Science and Energy & Environment fields and perpetuate corporate mission of “TechnoAmenity: Providing prosperity and comfort to people and society, with our unique technology”.
MilliporeSigma
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is committed to advancing cancer research. Our extensive portfolio of over 300,000 products supports the development of novel therapies, diagnostics, and prevention strategies. We offer solutions across key areas, including molecular tools, sample preparation, antibodies, cell culture, live cell analysis, biochemicals, and biomarker immunoassays. Cancer research is a multidisciplinary effort, and we provide integrated tools that accelerate progress at every stage—from basic to clinical research. Our molecular tools allow researchers to study cancer’s genetic and molecular foundations, while our high-quality antibodies enable the detection of proteins involved in cancer progression. MilliporeSigma also offers advanced sample preparation technologies for analyzing DNA, RNA, and proteins from tumor samples, and live cell analysis platforms for real-time insights into cellular behaviors and drug responses. Our biomarker immunoassays help identify cancer biomarkers and monitor treatment efficacy, supporting the development of early detection tests and personalized medicine. We are dedicated to empowering researchers with innovative solutions that help advance cancer prevention, detection, and treatment. MilliporeSigma is your trusted partner in tackling cancer biology complexities, accelerating breakthroughs, and realizing a future where cancer is more treatable and preventable. | As a leading science and technology company, we uniquely combine three specialized, innovation-driven businesses: Life Science, Healthcare, and Electronics. We utilize our multi-industry expertise to address a wide spectrum of global challenges. By supplying advanced scientific research and biotechnological manufacturing products, developing therapies for serious diseases, and providing high-performance materials for semiconductors and displays, we contribute to improving health, scientific progress, and technology for people around the world. | MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany. We are built to serve you in your drug development journey – as one trusted partner. Whether you need Millipore® CTDMO services, with decades of development, manufacturing, and testing expertise, to deliver a streamlined experience, or standalone industry-leading BioReliance® contract testing services and analytical development, we are built to serve you – to accelerate your milestones and breakthroughs. | MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, leverages over 35 years of CDMO experience and 75 years of contract testing services to redefine the industry CDMO model for today’s dynamic market needs. Our integrated Millipore® CTDMO Services offer expertise in development, manufacturing, contract testing, and technologies from pre-clinical to commercial stages, serving as a single experienced partner to accelerate your milestones and breakthroughs. With extensive experience in mRNA & LNP Formulation, ADC, Small Molecule, Biologics, and Viral Vector, we are dedicated to supporting your drug development journey as a trusted partner. Whether you seek a streamlined experience with a single partner or standalone industry-leading BioReliance® contract testing services and analytical development, we are committed to accelerating your milestones and breakthroughs while forging partnerships aimed at bringing breakthroughs to life to ultimately help patients. 2025 North America Advance Biotech Grant Award Ceremony Join us in the Start-up Stadium at 1:30pm, June 17th, to hear from our finalists and discover who will receive $258,000 in bioprocessing technologies, bioprocessing consulting services, contract testing services, and a full subscription to Emprove® Premium. The next round of applications will open in early 2026. | From the first spark of discovery to full-scale manufacturing, we stand beside you with the products, services, and expertise to help you move with speed and confidence. As a global leader in life science, MilliporeSigma supports innovators across biotech and pharma with 300,000+ products and comprehensive solutions all designed to help you progress from early research through process development, scale-up, and manufacturing. What you can explore with us: • Lab essentials and workflows to keep research moving day to day • Water purification systems for consistent lab performance • Raw and starting materials to support reliable manufacturing • Bioprocessing solutions and customized systems for your unique process needs • Ultrafiltration and downstream technologies to support scalable production • Contract testing and CDMO services to help you advance programs and meet quality requirements Whether you’re advancing a lead candidate, scaling a platform, or strengthening manufacturing readiness, we’ll connect you with experts who can help. | MilliporeSigma, the U.S. life science business of Merck KGaA, Darmstadt, Germany, partners with food safety teams to enable you to improve lab testing efficiencies with reliable products and services that meet ever changing regulations. It is through our collaborations that we can advance the safety and analysis of foods and beverages using trusted brands like Millipore® with microbiology solutions for hygiene, environmental monitoring & pathogen detection, Supelco® analytical solutions for analysis of food contamination and authenticity, Milli-Q® lab water solutions and Sigma Aldrich lab & production materials, including chemicals, inorganics & solvents throughout the supply chain, manufacturing and distribution. | MilliporeSigma is the U.S. life science business of Merck KGaA, Darmstadt, Germany. MilliporeSigma’s portfolio spans more than 300,000 products enabling scientific discovery. MilliporeSigma has customers in life science companies, university and government institutions, hospitals and industry. More than 1 million scientists and technologists use its products. The company is committed to solving the toughest problems in life science by collaborating with the global scientific community. | MilliporeSigma is the U.S. life science business of Merck KGaA, Darmstadt, Germany. With 19,000 employees and 72 manufacturing sites worldwide, MilliporeSigma’s portfolio spans more than 300,000 products enabling scientific discovery. MilliporeSigma has customers in life science companies, university and government institutions, hospitals and industry. More than 1 million scientists and technologists use its products. The company is committed to solving the toughest problems in life science by collaborating with the global scientific community. For more information, www.emdmillipore.com and www.sigma-aldrich.com.